Is There a Role for Cabozantinib in the First-Line Setting in Advanced RCC in Certain Populations?


Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.

Tian Zhang, MD: Dr Bilen, how comfortable are we using cabozantinib as a first-line treatment option, given the recent availability of adjuvant therapies in addition to cabozantinib in combination in the frontline setting?

Mehmet A. Bilen, MD: In general, cabozantinib has a broad data set, like in RCC [renal cell carcinoma]. First, was the METEOR trial in the salvage setting. Then, CABOSUN in the front-line setting. Most recently, CheckMate 9ER showed the efficacy of cabozantinib with immune checkpoint inhibitors. Thus, we know this agent is working in different lines. In addition, there are a number of real-world data also showing the effectiveness of cabozantinib plus VEGF plus I/O [immuno-oncology]. Because of this, cabozantinib is 1 agent we use after adjuvant immunotherapy.

Dr [David] Braun mentioned earlier that the type of failure from adjuvant immunotherapy is very important. If this is a failure that happened during, if this is a rapid failure, and if we see problem sites of metastases like the bone and liver, then this is 1 drug I use as a single agent or with immune checkpoint inhibitors.

This transcript has been edited for clarity.

Related Videos
Experts on RCC
Stefan Maksimovic, MD
Jose A. Karam, MD, FACS
Eric Jonasch, MD
Ulka Nitin Vaishampayan, MBBS
A panel of 6 experts on breast, lung, and gastrointestinal cancers
A panel of 4 experts on bladder cancer seated at a long table
A panel of 4 experts on bladder cancer seated at a long table